Based on analysis of 3 sections of legislative text.

• Requires VA to run a randomized, two‑year demonstration comparing FDA‑cleared OTC hearing aids to audiologist‑fitted prescription devices.
• Demo must start within one year, include at least two VA facilities across different networks, and include rural and urban settings.
• Eligibility hinges on VA enrollment, audiologist determination that OTC is appropriate, absence of FDA red flags, and access to a smartphone or Wi‑Fi for device personalization.
• Measures both self‑reported benefit and objective speech‑in‑noise outcomes, plus fiscal impact and cost comparisons.
• VA must consult consumer/stakeholder groups and submit an interim report at one year and a final report within 180 days after completion with a coverage recommendation.
• GAO must study national need and coverage for mild‑to‑moderate hearing loss and report to Congress within 18 months with recommendations.
• Defines FDA‑cleared OTC hearing aids as devices cleared under the FDA OTC pathway that include personalization technology (apps, software, in‑device testing).
• The legislation directs evaluation and reporting but does not itself appropriate funds or immediately change benefit entitlement.